| Literature DB >> 32652938 |
Xiaoxi Zhou1, Jianfeng Zhou1, Jianping Zhao2.
Abstract
BACKGROUND: The rapid spread of coronavirus disease 2019 (COVID-19) was declared as an emerging public health threat by the World Health Organization. As various measures have been taken successfully to combat the epidemic caused by SARS-CoV-2, a growing number of fully recovered patients have been discharged from hospitals. However, some of them have relapsed. Little is known about the causes that triggered the relapse. CASEEntities:
Keywords: Case report; Extend isolation time; New corona virus; Protective antibodies; Recurrence
Mesh:
Substances:
Year: 2020 PMID: 32652938 PMCID: PMC7352096 DOI: 10.1186/s12879-020-05231-z
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1A timeline of treatment and clinical events with laboratory parameters. A timeline of treatments and clinical events and time course of LDH (green), ferritin (orange) and IL2R (green yellow) and lymphocyte number (pink) with the results of oropharyngeal swab tests for SARS-CoV-2: positive: red arrow; negative: light blue arrow
Fig. 2Chest CT findings. The lesions (indicated by red arrow) of CT scan detected on day 3 after symptom onset (a). Axial images showed bilateral ground-glass opacity and consolidation on day 9 (b) and the larger area of lesions were observed on day 10 (c). CT scan on day 17 showed significant improvement of lesions before the first discharge (d), and on day 27 at relapse showed consolidation with higher density (e). The sixth and seventh follow-up CT scans demonstrated increased lesions on day 32 (f) and subsequent reduction of damaged area on day 44 (g), respectively
The levels of anti-SARS-CoV-2 antibody
| Detection time point (days after ill onset) | IgM (AU/ml)a | IgG (AU/ml)a |
|---|---|---|
| 31 | 36.44 | 28.96 |
| 33 | 28.81 | 25.87 |
| 44 | 19.27 | 24.68 |
aThe normal value of anti-SARS-CoV-2 antibodies is lower than 10 AU/ml